Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Johnson & Johnson announced the submission of two supplemental Biologics License Applications to the FDA seeking approval of TREMFYA ...

Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr ...

Collaboration with Janssen aims to fast-track the launch and enhance accessibility to YESINTEK for patients in need.

YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients ...